Navigation Links
Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
Date:8/13/2008

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, August 13 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that since July 3, 2008 it has acquired 81% of the shares in Jerini AG through its wholly owned indirect subsidiary Shire Deutschland Investments GmbH (formerly Maia Elfte Vermogensverwaltungs-GmbH), which today also published an Offer Document in respect of the remaining outstanding shares in Jerini.

The intention to make the voluntary takeover offer for a cash consideration of EUR6.25 per share was announced on July 3, 2008.

The offer period will expire on 10 September 2008, 24.00 CEST and the offer can be accepted until the last day of any additional acceptance period.

A copy of the Offer Document is published on Shire's website at http://www.shire.com. Details of market purchases after the publication of the Offer Document will also appear on Shire's website.

Important Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares in Jerini AG, nor an offer to purchase or sell any other securities. The terms and conditions of the Offer are being published in the offer document as approved by BaFin. Investors and holders of shares in Jerini AG are strongly advised to read the relevant documents regarding the takeover offer published by Shire Deutschland Investments GmbH, in particular the offer document, because they contain important information. Investors and holders of shares in Jerini AG may review these documents at the web site http://www.shire.com.

Notice to US holders of Jerini shares

In accordance with normal German market practice, and pursuant to exemptive relief granted by the SEC, the Bidder or its nominees or brokers (acting as agents) may from time to time make ce
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
2. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
3. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
4. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
5. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
6. Application for Listing of Shire Limited Ordinary Shares
7. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
8. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
9. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
10. New Shire Holding Company Proposal
11. Shire to Introduce a New UK Listed Holding Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... , August 26, 2015 ... factors fueling the optimism in biotech,s forecast is ... and life sciences advancements.  Active biotechnology & healthcare ... BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, ... Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest products ... during bacterial or fungal fermentation process development. , The new centrifuge greatly ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... cells is vital for our bodies to function. Part ... called neurotransmitters. The vesicle fuses with the nerve cell ... the next nerve cell. It is crucial that new ... continuously to take place. If parts of this communication ...
... Cleveland Clinic initiates dosing in ASSERT Trial , TSX ... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today ... Phase 2 clinical trial lead by Cleveland Clinic. This ... for the treatment of atherosclerosis, in patients with stable ...
... , SHANGHAI, Dec. 22 ... in China, announced today that,the company has received 2009 Deloitte ... year to win this award. The news was,announced at a ... Kong. , The Deloitte Technology Fast ...
Cached Biology Technology:New insight in nerve cell communication 2Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 2Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 3Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 4
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... at the University of Toronto, The Hospital for Sick ... British Columbia have identified a new treatment target for ... estimated 10% of common colds. The virus, called human ... reason for hospitalization of infants and children under two ...
... August 16th issue of Developmental Cell , researchers at ... that new blood vessels form in the right place and ... long time that blood vessels branch to give rise to ... this branching occurs with a reproducible pattern. However, the mechanisms ...
... A study out of York University has some refreshing ... Published today in the journal Applied Physiology, Nutrition and ... otherwise healthy live just as long as their slim counterparts, ... "Our findings challenge the idea that all obese individuals ...
Cached Biology News:Researchers map pathway of infection for a common, potentially life-threatening respiratory virus 2Fat and healthy? York U study finds slim isn't always superior 2
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Request Info...
Recombinant Mouse Wnt-3a...
... There are at least 20 structurally ... of the TGF-beta superfamily. BMPs were originally ... bone formation. They are also involved in ... organs. BMPs regulate the growth, differentiation, chemotaxis ...
Biology Products: